Stop Smuggling Illicit Synthetic Drugs on U.S. Transportation Networks Act of 2024, Section 103. "Development of strategy to accelerate research and development of non-intrusive, advanced inspection technologies to detect illicit synthetic drugs"

Proposed 2024-09-25 | Official source

Summary

Develops a joint strategy to accelerate research, development, and deployment of AI and other technologies to detect illicit synthetic drugs. Requires report submission to specified congressional committees within two years.

This machine-generated summary is awaiting review by an AGORA editor. Use with caution.

Key facts

🏛️ This document was proposed and/or enacted by the United States Congress but is now defunct. For authoritative text and metadata, visit the official source.

📜 This document's name is Stop Smuggling Illicit Synthetic Drugs on U.S. Transportation Networks Act of 2024. AGORA also tracks this document under the name Stop Smuggling Illicit Synthetic Drugs on U.S. Transportation Networks Act of 2024, Section 103. "Development of strategy to accelerate research and development of non-intrusive, advanced inspection technologies to detect illicit synthetic drugs". It is part of Stop Smuggling Illicit Synthetic Drugs on U.S. Transportation Networks Act of 2024.

↳ This document is part of a longer one: Stop Smuggling Illicit Synthetic Drugs on U.S. Transportation Networks Act of 2024. Some AGORA documents are "split off" from longer documents that mix AI and non-AI content, such as omnibus authorization or appropriations laws in the United States Congress. Read more >>

Themes AI risks, applications, governance strategies, and other themes addressed in AGORA documents.

Thematic tags are in progress.

Full text

This is an unofficial copy. The document has been archived and reformatted in plaintext for AGORA. Footnotes, tables, and similar material may be omitted. For the official text, visit the original source.

SEC. 103. Development of strategy to accelerate research and development of non-intrusive, advanced inspection technologies to detect illicit synthetic drugs. (a) Defined term.—In this section, the term “appropriate congressional committees” means— (1) the Committee on Commerce, Science, and Transportation of the Senate; (2) the Committee on Homeland Security and Governmental Affairs of the Senate; (3) the Committee on Finance of the Senate; (4) the Committee on the Judiciary of the Senate; (5) the Committee on Energy and Commerce of the House of Representatives; (6) the Committee on Homeland Security of the House of Representatives; (7) the Committee on Financial Services of the House of Representatives; and (8) the Committee on the Judiciary of the House of Representatives.

(b) In general.—The Director of the Office of Science and Technology Policy and the Director of the Office of National Drug Control Policy, in consultation and coordination with the Director of the National Science Foundation, the Secretary of Commerce (acting through the Director of the National Institute of Standards and Technology), the Secretary of Energy, the Secretary of Homeland Security, the Administrator of the Transportation Security Administration, and the Attorney General, shall— (1) develop a joint strategy to accelerate research and development and deployment of non-intrusive, advanced inspection technologies and other advanced inspection technologies to detect illicit synthetic drugs, such as artificial intelligence and quantum hybrid computing and integration of multiple data sources; and (2) not later than 2 years after the date of the enactment of this Act, submit a report on such strategy to the appropriate congressional committees.